In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr. 129/22 of the ethics commssion of the university Ulm.
According to the recommendations, IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight. 28-day mortality and 30-day time course of leukocyte counts and serum concentrations of C-reactive protein (CRP), procalcitonin (PCT), interleukin 6 (IL-6) and ferritin in 4 patient groups, i. e., treated without (N) or with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T), were evaluated.
Study Type
OBSERVATIONAL
Enrollment
95
IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
Clinic of Anesthesiology
Ulm, Germany
Mortality rates in the 4 groups
Number of survivors and nonsurvivors
Time frame: 28-day mortality
Leukocyte count in 4 groups
Routine blood analysis
Time frame: 30-days
C-reactive protein in 4 groups
Routine blood analysis over time
Time frame: 30-days
Interleukin 6 serum concentrations in 4 groups
Routine blood analysis over time
Time frame: 30-days
Ferritin serum concentrations in 4 groups
Routine blood analysis over time
Time frame: 30-days
Procalcitonin serum concentrations in 4 groups
Routine blood analysis over time
Time frame: 30-days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.